Literature DB >> 9812218

Biology of the scleroderma fibroblast.

D Strehlow1, J H Korn.   

Abstract

Abnormalities of matrix biosynthesis by systemic sclerosis fibroblasts underlie the cutaneous and visceral fibrosis seen in this disease. The fundamental basis of the abnormal fibroblast phenotype has not been determined but primary metabolic abnormalities, responses to abnormal environmental signals, and clonal selection have all been hypothesized to play a role. In the past year, evidence supporting each of these explanations was forthcoming. In a study of Choctaw Indians with a high incidence of scleroderma, it was shown that genetic linkage to fibrillin may play a role. This should be considered in light of demonstrated abnormalities of fibrillin structure in the tight skin mouse. Other studies have shown that abnormalities of transforming growth factor beta receptor levels, abnormalities of production and response to tissue inhibitor of matrix metal-loproteinase, and abnormalities of response to endothelial cell factors are all present in scleroderma fibroblasts. In addition to these studies in scleroderma fibroblasts, work elucidating the role of transcription factors Sp1, Sp3, and cKrox in regulating collagen metabolism provided important data upon which future studies may build.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9812218     DOI: 10.1097/00002281-199811000-00011

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  14 in total

Review 1.  Interactions of fibroblasts with the extracellular matrix: implications for the understanding of fibrosis.

Authors:  B Eckes; D Kessler; M Aumailley; T Krieg
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.

Authors:  Thomas A Wynn
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

3.  Increased sensitivity to extracellular ATP of fibroblasts from patients affected by systemic sclerosis.

Authors:  Andrea Lo Monaco; Sara Gulinelli; Gabriella Castellino; Anna Solini; Davide Ferrari; Renato La Corte; Francesco Trotta; Francesco Di Virgilio
Journal:  Ann Rheum Dis       Date:  2007-08       Impact factor: 19.103

4.  P2X(7) Receptors in Neurological and Cardiovascular Disorders.

Authors:  Stephen D Skaper; Patrizia Debetto; Pietro Giusti
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-06-24

5.  Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma).

Authors:  M Matucci-Cerinic; R Giacomelli; A Pignone; M L Cagnoni; S Generini; R Casale; P Cipriani; A Del Rosso; P Tirassa; Y T Konttinen; B M Kahaleh; P S Fan; M Paoletti; C Marchesi; M Cagnoni; L Aloe
Journal:  Ann Rheum Dis       Date:  2001-05       Impact factor: 19.103

6.  B cells: no longer bystanders in liver fibrosis.

Authors:  Rashpal K Bhogal; Constantin A Bona
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

Review 7.  Cellular and molecular mechanisms of fibrosis.

Authors:  T A Wynn
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 8.  The immune pathogenesis of scleroderma: context is everything.

Authors:  Matthew B Greenblatt; Antonios O Aliprantis
Journal:  Curr Rheumatol Rep       Date:  2013-01       Impact factor: 4.592

Review 9.  New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma.

Authors:  David J Abraham; Beate Eckes; Vineeth Rajkumar; Thomas Krieg
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

10.  The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis.

Authors:  Theresa C Barnes; Marina E Anderson; Robert J Moots
Journal:  Int J Rheumatol       Date:  2011-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.